Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Colorectal Cancer
Clinical trial register · United States · industry-sponsored

Colorectal Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 56 Florida 39 Texas 34 New York 29 Massachusetts 22
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Colorectal Cancer trials in the USA

84 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
IKS04 Regimen in Advanced Solid Tumors That Express CA242
NCT07738939Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
Iksuda Therapeutics Ltd.
Phase 1
120
California, Massachusetts, Tennessee, Texas
2026-11
Recruiting
GE Healthcare
Phase 2/3
175
Michigan
2026-10
Not yet open
A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT07743723Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
106
New York
2026-09
Recruiting
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, North Carolina
2026-07-28
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Dispatch Biotherapeutics
Phase 1
66
California, Florida, Massachusetts, Ohio, Tennessee, Utah
2026-04-13
Recruiting
GI Windows, Inc.
Not applicable
30
Florida, Texas
2026-04-01
Recruiting
Exero Medical Ltd.
Not applicable
80
Kentucky, Maryland, Nebraska, New York, Pennsylvania
2026-03-10
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT07189871Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
Radiopharm Theranostics, Ltd
Phase 1/2
61
Alabama, Michigan, Nebraska, Texas
2026-02-23
Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
Blue Earth Diagnostics
Phase 1/2
71
Texas
2026-02-19
Recruiting
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
By invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668Colorectal Cancer, Stoma - Ileostomy
SafeHeal Inc
Not applicable
108
California, Florida, Massachusetts, New York, North Carolina, Pennsylvania
2026-01-08
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
California, Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, New York
2025-04-28
Recruiting
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Urine Metabolites in the Diagnosis of Disease
NCT06710067Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Luventix, Inc.
Observational
1,250
California
2024-10-01
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
NCT06598007Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugFolfox
Crossignal Therapeutics, Inc.
Phase 1/2
78
Texas
2024-09-20
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Active, closed
Rgenta Therapeutics Inc
Phase 1
105
Massachusetts, Michigan, New York, Texas, Virginia, Washington
2024-08-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
Revolution Medicines, Inc.
Phase 1/2
1,130
Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts
2024-05-24
Recruiting
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Active, closed
Complement Theory Inc.
Not applicable
146
Delaware
2024-05-12
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Recruiting
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Recruiting
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
NCT06059963Colorectal Cancer, Advanced Adenocarcinoma
Universal Diagnostics
Observational
12,000
Virginia
2024-01-18
Recruiting
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma
JSR Medical Co., Ltd.
Not applicable
256
New York, Pennsylvania, Texas
2023-12-04
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Recruiting
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Guardant Health, Inc.
Observational
470
Illinois
2023-10-25
Active, closed
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826Advanced Solid Tumor, Colorectal Cancer
TORL Biotherapeutics, LLC
Phase 1
70
California, Colorado, Indiana, Missouri, Tennessee, Texas
2023-09-29
Active, closed
AgonOx, Inc.
Phase 1
18
Oregon
2023-06-19
Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
Parabilis Medicines, Inc.
Phase 1/2
619
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts
2023-05-23
Active, closed
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R
Elicio Therapeutics
Phase 1/2
158
Arizona, California, Colorado, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-14
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Recruiting
Phanes Therapeutics
Phase 1/2
350
California, Colorado, Iowa, Kentucky, Massachusetts, North Carolina, Pennsylvania, Texas
2023-03-15
Recruiting
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
TiumBio Co., Ltd.
Phase 1/2
140
Texas, Washington
2023-03-10
Active, closed
Exelixis
Phase 3
901
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2022-09-07
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
220
California, Rhode Island, Texas
2022-08-04
Recruiting
Lyell Immunopharma, Inc.
Phase 1/2
155
California, Colorado, Massachusetts
2022-08-01
Active, closed
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
HUYABIO International, LLC.
Phase 1
44
California, Florida, Michigan, Missouri, Ohio
2022-08-01
Recruiting
Tempus AI
Observational
300
Arkansas, California, Maryland, Missouri, Nebraska, North Carolina, Ohio, Oklahoma
2022-06-21
Active, closed
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
Poseida Therapeutics, Inc.
Phase 1
180
California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York
2022-02-15
Active, closed
Exact Sciences Corporation
Observational
1,017
California, Florida, Illinois, Iowa, Kansas, Maryland, Minnesota, Missouri
2021-12-15
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
NCT05219734Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Invitae Corporation
Observational
400
Indiana, North Carolina
2021-11-29
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
A2 Biotherapeutics Inc.
Observational
500
Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio
2021-10-29
Active, closed
AbbVie
Phase 1
520
California, Colorado, Connecticut, Illinois, Indiana, Louisiana, Michigan, New York
2021-10-13
Active, closed
da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures
NCT04403022Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors
Intuitive Surgical
Not applicable
60
Florida, Michigan, Minnesota, Nevada, Pennsylvania, Texas, Washington
2021-06-03
Recruiting
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
BioEclipse Therapeutics
Phase 1
60
Arizona, California
2021-01-08
Active, closed
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Kahr Medical
Phase 1/2
125
California, Colorado, Florida, Indiana, Kansas, Pennsylvania
2020-10-07
Recruiting
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Bold Therapeutics, Inc.
Phase 1/2
220
California, Florida
2020-08-28
Active, closed
Genentech, Inc.
Phase 1
498
California, Connecticut, Florida, Massachusetts, New York, Oklahoma, Pennsylvania
2020-07-29
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
Bicara Therapeutics
Phase 1
473
California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Rhode Island
2020-06-01
Active, closed
Guardant Health, Inc.
Observational
44,467
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2019-10-08
Active, closed
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
NCT04046445Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
Amal Therapeutics
Phase 1
96
Arizona, California, Colorado, New York, North Carolina, Texas
2019-07-22
Recruiting
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
IDEAYA Biosciences
Phase 1/2
336
California, Colorado, Iowa, Michigan, New York, North Carolina, Ohio, Pennsylvania
2019-06-28
Active, closed
Toray Industries, Inc
Phase 1
138
Arizona, California, Louisiana, New Jersey, New York, Oregon, Texas, Virginia
2019-04-26
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Merus B.V.
Phase 1/2
560
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, New York
2018-05-02
Recruiting
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Lumicell, Inc.
Phase 1/2
66
Massachusetts
2016-08-04
Active, closed
Hoffmann-La Roche
Phase 2
534
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2015-11-19
Rows per page Showing 1–84 of 84
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/colorectal-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 84 of those studies listing the condition Colorectal Cancer.

How many Colorectal Cancer trials are recruiting in the US?

55 of the 84 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 25 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorectal Cancer), 84 studies
PhaseStudiesRecruitingShare
Phase 1291434.5%
Phase 1/2252029.8%
Observational9610.7%
Phase 29710.7%
Not applicable637.1%
Phase 3434.8%
Phase 2/3111.2%
Phase 4111.2%

Most active sponsors

Lead sponsors with the most studies (Colorectal Cancer)
Lead sponsorStudiesRecruiting
A2 Biotherapeutics Inc.33
AbbVie32
Eli Lilly and Company21
Exelixis21
Guardant Health, Inc.21
HUYABIO International, LLC.20
IDEAYA Biosciences22
Merck Sharp & Dohme LLC21
Revolution Medicines, Inc.22
Universal Diagnostics22

Top states

Top states (Colorectal Cancer), by number of studies with a site there
StateStudies
California56
Florida39
Texas34
New York29
Massachusetts22
Colorado21
Michigan20
Arizona19
Pennsylvania17
Georgia15
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.